Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2004-03-29
2010-06-08
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S205100, C424S224100, C424S281100, C435S235100, C435S320100, C435S069100
Reexamination Certificate
active
07731974
ABSTRACT:
The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.
REFERENCES:
patent: 4215051 (1980-07-01), Schroeder et al.
patent: 4769330 (1988-09-01), Paoletti et al.
patent: 6022726 (2000-02-01), Palese et al.
patent: 6110461 (2000-08-01), Lee et al.
patent: 6296845 (2001-10-01), Sampson-Johannes et al.
patent: 6440422 (2002-08-01), Sutter et al.
patent: 6451323 (2002-09-01), Garcia-Sastre et al.
patent: 6468544 (2002-10-01), Egorov et al.
patent: 6497873 (2002-12-01), Whitt et al.
patent: 6531123 (2003-03-01), Chang
patent: 2005/0260601 (2005-11-01), Whitt et al.
patent: WO96/03997 (1996-02-01), None
patent: WO97/26904 (1997-07-01), None
patent: WO99/18799 (1999-04-01), None
patent: WO00/62735 (2000-10-01), None
patent: WO01/19380 (2001-03-01), None
patent: WO2004/022716 (2004-03-01), None
Desforges et al (Virus Research 76:87-102, 2001).
Lichty et al, Journal of Virology 87:3379-3384, 2006.
Desforges et al, Virus Research 76:87-102, 2001.
Descotes et al (Expert Opinion on Drug Metabolism and Toxicology 4:1537-1549, 2008).
Barber (Viral Immunology 17(4): 516-527, 2004).
Petersen, et al., “The Matrix Protein of Vesicular Stomatitis Virus Inhibits Nucleocytoplasmic Transport When it is in the Nucleus and Associated with Nuclear Pore Complexes”, Molecular and Cellular Biology, vol. 20, No. 22, Nov. 2000, pp. 8590-8601.
Desforges, et al.,“Different host-cell shutoff strategies related to the maxtrix protein lead to persistence of vesicular stomatitis virus mutant on fibroblast cell”, Virus Research, vol. 76, No. 1, Jul. 2001, pp. 87-102.
von Kobbe, et al., “Vesicular Stomatitis Virus Matrix Protein Inhibits Host Cell Gene Expression by Targeting the Nucleoporin Nup98”, Molecular Cell, vol. 6, Nov. 2000, pp. 1243-1252.
Desforges, et al., “Matrix Protein Mutations Contribute to Inefficient Induction of Apoptosis Leading to Persistent Infection of Human Neural Cells by Vesicular Stomatitis Virus”, Virology, vol. 295, No. 1, Mar. 2002, pp. 63-73.
Jayakar, et al., “Identification of Two Additional Translation Products from the Matrix (M) Gene That Contribute to Vesicular Stomatitis Virus Cytopathology”, Journal of Virology, vol. 76, No. 16, Aug. 2002, pp. 8011-8018.
Stojdl, et al., “Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus”, Nature Medicine, vol. 6, No. 7, Jul. 2000, pp. 821-825.
Balachandran, et al., “Oncolytic Activity of Vesicular Stomatitis Virus is Effective against Tumor Exhibiting Aberrant p53, Ras, or Myc Function and involves the Induction of Apoptosis”, Journal of Virology, vol. 75, No. 7, Apr. 2001, pp. 3474-3479.
Petersen, et al., “Multiple vesiculoviral matrix proteins inhibit both nuclear export and import”, Proceedings of the National Academy of Science of the United States of America, vol. 98, No. 15, Jul. 2001, pp. 8590-8595.
Stojdl, et al., “VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents”, Cancer Cell, vol. 4, No. 4, Oct. 2003, pp. 263-275.
Ahmed, et al., “Ability of the Matrix Protein of Vesicular Stomatitis Virus to Suppress Beta Interferon Gene Expression is Genetically Correlated with the Inhibition of Host RNA and Protein Synthesis”, Journal of Virology, vol. 77, No. 8, Apr. 2003, pp. 4646-4657.
Specht, et al., “Dendritic Cells Retrovirally Transduced with a Model Antigen Gene are Therapeutically Effective against Established Pulmonary Metastases”, The Journal of Experimental Medicine, vol. 186, No. 8, Oct. 1997, pp. 1213-1221.
Terstegen, et al., “The Vesicular Stomatitis Virus Matrix Protein Inhibits Glycoprotein 130-Dependent STAT Activation”, The Journal of Immunology, vol. 167, 2001, pp. 5209-5216.
Her, et al., “Inhibition of Ran Guanosine Triphosphatase-Depenedent Nuclear Transport by the Matrix Protein of Vesicular Stomatitis Virus”, Science, vol. 276, Jun. 1997, pp. 1845-1847.
Lu, et al., “Regulation of the Promoter Activity of Interferon Regulatory Factor-7 Gene”, The Journal of Biological Chemistry, vol. 275, No. 41, Oct. 2000, pp. 31805-31812.
Zhang, et al., “IRF-7, a New Interferon Regulatory Factor Associated with Epstein-Barr Virus Latency”, Molecular and Cellular Biology, vol. 17, No. 10, Oct. 1997, pp. 5748-5757.
Wathelet, et al., “Virus Infection Induces the Assembly of Coordinately Activated Transcription Factors on the IFN-B Enhancer in Vivo”, Molecular Cell, vol. 1, Mar. 1998, pp. 507-518.
Lawson, et al., “Recombinant Vesicular Stomatitis Viruses from DNA”, Proc. Natl. Acad. Sci., vol. 92, May 1995, pp. 4477-4481.
Novella, et al., “Large-Population Passages of Vesicular Stomatitis Virus in Interferon-Treated Cells Select Variants of Only Limited Resistance”, Journal of Virology, vol. 70, No. 9, Sep. 1996, pp. 6414-6417.
Yuan, et al., “Inhibition of Host Transcription by Vesicular Stomatitis Virus Involves a Novel Mechanism that is Independent of Phosphorylation of TATA-Binding Protein (TBP) or Association of TBP with TBP-Associated Factor Subunits”, Journal of Virology, vol. 75, No. 9, May 2001, pp. 4453-4458.
Lin, et al., “Multiple Regulatory Domains Control IRF-7 Activity in Response to Virus Infection”, The Journal of Biological Chemistry, vol. 275, No. 44, Nov. 2000, pp. 34320-34327.
Bell, et al., “Getting Oncolytic Virus Therapies off the Ground”, Cancer Cell, vol. 4, Jul. 2003, pp. 7-11.
Ferran, et al., “The Vesicular Stomatitis Virus Matrix Protein Inhibits Transcription from the Human Beta Interferon Promoter”, Journal of Virology, vol. 71, No. 1, Jan. 1997, pp. 371-377.
Zhang, et al., “Interferon Regulatory Factor 7 Mediates Activation of Tap-2 by Epstein-Barr Virus Latent Membrane Protein 1”, Journal of Virology, vol. 75, No. 1, Jan. 2001, pp. 341-350.
Stojdl, et al., “The Murine Double-Stranded RNA-Dependent Protein Kinase PKR is Required for Resistance to Vesicular Stomatitis Virus”, Journal of Virology, vol. 74, No. 20, Oct. 2000, pp. 9580-9585.
Steinhoff, et al., “Antiviral Protection by Vesicular Stomatitis Virus-Specified Antibodies in Alpha/Beta Interferon Receptor-Deficient Mice”, Journal of Virology, vol. 69, No. 4, Apr. 1995, pp. 2153-2158.
Jayakar, et al., “Mutation in the PPPY Motif of Vesicular Stomatitis Virus Matrix Protein Reduce Virus Budding by Inhibiting a Late Step in Virion Release”, Journal of Virology, vol. 74, No. 21, Nov. 2000, pp. 9818-9827.
Racaniello, et al., “Cloned Poliovirus Complementary DNA is Infectious in Mammalian Cells”, Science, vol. 214, Nov. 1981, pp. 916-918.
Roberts, et al., “Recovery of Negative-Strand RNA Viruses from Plasmid DNAs: A Positive Approach Revitalizes a Negative Field”, Virology, vol. 247, 1998, pp. 1-6.
Necomb, et al., “In Vitro Reassembly of Vesicular Stomatitis Virus Skeletons”, Journal of Virology, vol. 41, No. 3, Mar. 1982, pp. 1055-1062.
Blondel, et al., “Role of Matrix Protein in Cytopathogenesis of Vesicular Stomatitis Virus”, Journal of Virology, vol. 64, No. 4, Apr. 1990, pp. 1716 -1725.
Lyles, et al., “Potency of Wild-type and Temperature-Sensitive Vesicular Stomatitis Virus Matrix Protein in the Inhibition of Host-Directe
Bell John C.
Lichty Brian D.
Stojdl David F.
Golightly Douglas A.
Kreisler Lewis J.
Mosher Mary E
Ottawa Hospital Research Institute
Wellstat Biologics Corporation
LandOfFree
Mutant vesicular stomatitis viruses and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mutant vesicular stomatitis viruses and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutant vesicular stomatitis viruses and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4236507